β-Blockade in Chronic Heart Failure
| Autor: | de Rudolf Boer, van Dirk Veldhuisen |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
medicine.medical_specialty
Ejection fraction business.industry medicine.disease humanities Blockade Bisoprolol Physiology (medical) Heart failure Anesthesia Internal medicine medicine Cardiology cardiovascular diseases Cardiology and Cardiovascular Medicine Peak vo2 Beta (finance) business human activities Carvedilol circulatory and respiratory physiology medicine.drug Metoprolol |
| Zdroj: | Circulation. 103 |
| ISSN: | 1524-4539 0009-7322 |
| DOI: | 10.1161/01.cir.103.23.e118 |
| Popis: | To the Editor: We read with great interest the article by Metra et al1 that was recently published in the Journal. Although β-blockade in chronic heart failure (CHF) emerged as a powerful treatment modality, it remains unclear whether there is a difference between the various agents, such as the β1-selective blockers bisoprolol and metoprolol and the nonselective β-blocker carvedilol. The authors compared response to carvedilol or metoprolol by measuring various clinical parameters, such as left ventricular ejection fraction (LVEF) and peak Vo2. They found that both carvedilol and metoprolol improved these parameters but that carvedilol did so primarily for LVEF and metoprolol for peak Vo2. This is an interesting but somewhat contradictory finding that suggests a possible difference in the working profile of these 2 compounds. There are 2 assertions in this article that … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|